BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 8779685)

  • 1. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
    Newell KA; Alonso EM; Whitington PF; Bruce DS; Millis JM; Piper JB; Woodle ES; Kelly SM; Koeppen H; Hart J; Rubin CM; Thistlethwaite JR
    Transplantation; 1996 Aug; 62(3):370-5. PubMed ID: 8779685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children.
    Newell KA; Alonso EM; Kelly SM; Rubin CM; Thistlethwaite JR; Whitington PF
    J Pediatr; 1997 Jul; 131(1 Pt 1):98-104. PubMed ID: 9255199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus.
    Sokal EM; Antunes H; Beguin C; Bodeus M; Wallemacq P; de Ville de Goyet J; Reding R; Janssen M; Buts JP; Otte JB
    Transplantation; 1997 Nov; 64(10):1438-42. PubMed ID: 9392308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
    Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV; Jordan S; Kim GS; Toyoda M; Goss JA; Vargas JH; Martín MG; Bahar R; Maxfield AL; Ament ME; Busuttil RW
    Transplantation; 1998 Dec; 66(12):1604-11. PubMed ID: 9884246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression.
    Shapiro R; Nalesnik M; McCauley J; Fedorek S; Jordan ML; Scantlebury VP; Jain A; Vivas C; Ellis D; Lombardozzi-Lane S; Randhawa P; Johnston J; Hakala TR; Simmons RL; Fung JJ; Starzl TE
    Transplantation; 1999 Dec; 68(12):1851-4. PubMed ID: 10628763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression.
    Ellis D; Jaffe R; Green M; Janosky JJ; Lombardozzi-Lane S; Shapiro R; Scantlebury V; Vivas C; Jordan ML
    Transplantation; 1999 Oct; 68(7):997-1003. PubMed ID: 10532541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy.
    Cacciarelli TV; Green M; Jaffe R; Mazariegos GV; Jain A; Fung JJ; Reyes J
    Transplantation; 1998 Oct; 66(8):1047-52. PubMed ID: 9808490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of quantitative Epstein-Barr virus polymerase chain reaction and preemptive immunosuppression reduction in pediatric liver transplantation: a preliminary experience.
    Kogan-Liberman D; Burroughs M; Emre S; Moscona A; Shneider BL
    J Pediatr Gastroenterol Nutr; 2001 Oct; 33(4):445-9. PubMed ID: 11698761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr virus infections in children after transplantation of the small intestine.
    Finn L; Reyes J; Bueno J; Yunis E
    Am J Surg Pathol; 1998 Mar; 22(3):299-309. PubMed ID: 9500771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational management of posttransplant lymphoproliferative disorder in pediatric recipients.
    Praghakaran K; Wise B; Chen A; Schwarz K; Colombani P
    J Pediatr Surg; 1999 Jan; 34(1):112-5; discussion 115-6. PubMed ID: 10022154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein-Barr virus infection in children following liver transplantation.
    Cao S; Cox K; Esquivel CO; Berquist W; Concepcion W; Ojogho O; Monge H; Krams S; Martinez O; So S
    Transplantation; 1998 Oct; 66(7):851-6. PubMed ID: 9798693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
    Guthery SL; Heubi JE; Bucuvalas JC; Gross TG; Ryckman FC; Alonso MH; Balistreri WF; Hornung RW
    Transplantation; 2003 Apr; 75(7):987-93. PubMed ID: 12698085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease.
    Smets F; Latinne D; Bazin H; Reding R; Otte JB; Buts JP; Sokal EM
    Transplantation; 2002 May; 73(10):1603-10. PubMed ID: 12042647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation.
    Hurwitz M; Desai DM; Cox KL; Berquist WE; Esquivel CO; Millan MT
    Pediatr Transplant; 2004 Jun; 8(3):267-72. PubMed ID: 15176965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of aciclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol.
    Birkeland SA; Andersen HK; Hamilton-Dutoit SJ
    Transplantation; 1999 May; 67(9):1209-14. PubMed ID: 10342310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreasing incidence of symptomatic Epstein-Barr virus disease and posttransplant lymphoproliferative disorder in pediatric liver transplant recipients: report of the studies of pediatric liver transplantation experience.
    Narkewicz MR; Green M; Dunn S; Millis M; McDiarmid S; Mazariegos G; Anand R; Yin W;
    Liver Transpl; 2013 Jul; 19(7):730-40. PubMed ID: 23696264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.
    Ganschow R; Schulz T; Meyer T; Broering DC; Burdelski M
    J Pediatr Gastroenterol Nutr; 2004 Feb; 38(2):198-203. PubMed ID: 14734884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus.
    Cao S; Cox KL; Berquist W; Hayashi M; Concepcion W; Hammes GB; Ojogho OK; So SK; Frerker M; Castillo RO; Monge H; Esquivel CO
    Pediatr Transplant; 1999 Feb; 3(1):22-6. PubMed ID: 10359027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].
    Franco A; Jiménez L; Aranda I; Alvarez L; González M; Rocamora N; Olivares J
    Nefrologia; 2002; 22(5):463-9. PubMed ID: 12497748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.